Cytochrome P-450 CYP2C9

A cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.

Also Known As:

CYP2C9; CYPIIC9; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; CYP2C9, Cytochrome P-450; Cytochrome P 450 CYP2C9; Cytochrome P450 MP 4; Cytochrome P450 MP 8; Cytochrome P450 PB 1; MP-4, Cytochrome P450; MP-8, Cytochrome P450; P-450 CYP2C9, Cytochrome; P450 MP-4, Cytochrome; P450 MP-8, Cytochrome; P450 PB-1, Cytochrome; PB-1, Cytochrome P450

Networked: 736 relevant articles (31 outcomes, 176 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Agúndez, José A G: 8 articles (01/2021 - 06/2002)
2.	García-Martín, Elena: 8 articles (01/2021 - 06/2002)
3.	Sukasem, Chonlaphat: 7 articles (01/2022 - 05/2016)
4.	Yasar, Umit: 7 articles (10/2017 - 04/2002)
5.	Martínez, Carmen: 7 articles (01/2012 - 06/2002)
6.	Rettie, Allan E: 6 articles (01/2021 - 04/2002)
7.	Veenstra, David L: 6 articles (01/2017 - 04/2002)
8.	Loriot, Marie-Anne: 6 articles (04/2014 - 06/2007)
9.	Božina, Nada: 5 articles (02/2022 - 09/2013)
10.	Chung, Wen-Hung: 5 articles (01/2022 - 07/2016)

Related Diseases

1.	Hemorrhage 06/01/2018 - "Here, we aimed to investigate whether VKORC1 and CYP2C9 polymorphisms improved the predictive performance for major bleeding using the HAS-BLED score. " 07/01/2011 - "Six studies met the inclusion criteria, whereas three reported no results because there were no homozygous mutant genotypes for CYP2C92 and 3 in their samples, risk of bleeding was associated by one with the presence of CYP2C92 and by two with the CYP2C93 coding variant. " 06/01/2003 - "Some data suggest that the CYP2C9*2 variant is associated with an increased propensity for bleeding whereas other studies do not demonstrate a substantial risk of adverse events. " 05/01/2003 - "Several studies also suggest that possession of a CYP2C9 variant allele is associated with an increased risk of adverse events, such as bleeding. " 11/01/2000 - "The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurence of bleeding complications. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2018 - "In this study, we explored the effects of POR28 and combined CYP2C92 and CYP2C93 genotypes on SH and the efficacy of SU treatment in type 2 diabetes. " 01/01/2010 - "Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study." 08/16/2023 - "We, for the first time, investigated the association between the CYP2C9 variant alleles CYP2C92 and CYP2C93 and the incidence of hypoglycaemia in patients with Type 2 diabetes mellitus (T2DM) receiving sulphonylurea medications. " 08/16/2023 - "Association of CYP2C92 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population." 12/01/2021 - "A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients."
3.	Adenoma (Adenomas) 08/01/2004 - "Among 394 cases and 396 controls, women with at least 1 variant CYP2C9 allele had a significantly greater risk for adenoma (multivariate odds ratio [OR], 1.56; 95% confidence interval [CI], 1.13-2.15; P = 0.007). " 08/01/2021 - "49 mutations/ SNPs/ haplotypes in 23 genes/ chromosomal regions (KRAS, APC, EGFR, COX1/2, IL23R, DRD2, CYP2C9/24A1/7A1, UGT1A6, ODC, ALOX12/15, PGDH, SRC, IGSF5, KCNS3, EPHB1/ KY, FAM188b, 3p24.1, 9q33.2, 13q33.2) correlated with metachronous adenoma / advanced adenoma risk. " 01/01/2013 - "The adenoma risk was increased by 26 % (RR = 1.26, 95 % CI 0.99-1.58) for former smokers and 60 % (RR = 1.60, 95 % CI 1.19-2.15) for current smokers among wild-type individuals, but there was no increased risk among individuals with ≥1 variant allele (CYP2C92 or 3) (p (interaction) = 0.04). " 01/01/2013 - "The risk for advanced lesions or multiple (≥3) adenomas was increased by 64 % (RR = 1.64, 95 % CI 1.18-2.28) for ≥1 variant allele (CYP2C92 or 3) and 79 % (RR = 1.79, 95 % CI 1.16-2.75) for ≥1 CYP2C93 allele. " 01/01/2013 - "CYP2C9 genotype was associated with increased risks for adenoma recurrence of 29 % (RR = 1.29, 95 % CI 1.09-1.51) for ≥1 variant allele (CYP2C92 or 3) and 47 % (RR = 1.47, 95 % CI 1.19-1.83) for ≥1 CYP2C93 allele. "
4.	Ankylosing Spondylitis 04/12/2017 - "Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis." 04/12/2017 - "BACKGROUND The aim of this study was to evaluate the relationships of CYP2C9 and COX-2 genetic polymorphisms with therapeutic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in treatment of ankylosing spondylitis (AS). " 03/01/2017 - "Correlations of CYP2C93/CYP2D610/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study."
5.	Neoplasms (Cancer) 04/01/2010 - "For the combined carriers (any CYP2C92 or CYP2C93 heterozygotes or homozygotes) vs. non-carriers we had 90% statistical power to exclude measures of relative risks below/above 0.8/1.2 and 0.9/1.1 in the Copenhagen City Heart Study and below/above 0.8/1.3 and 0.9/1.1 in the Copenhagen General Population Study for tobacco-related cancer and all cancer, respectively. " 04/01/2010 - "In a prospective study of the general population (n=10 392) with 60 years of follow-up, the Copenhagen City Heart Study, we associated two variants of CYP2C9 (CYP2C92 and CYP2C93) with risk of tobacco-related cancer and all cancer. " 07/01/2022 - "Conclusions The CYP2C93 genetic polymorphism might play a significant role as a risk factor for the development of gastric malignancy irrespective of H. " 05/01/2021 - "CYP2C9 repression in collected ESCC patient tumor tissues was demonstrated by RT-qPCR and Western blot. " 12/01/2020 - "Our findings aid understanding the genetic polymorphism distribution of Cyp2C92 , Cyp2C9*3 , and VKORC1 in women with genital malignancies. "

Related Drugs and Biologics

1.	Warfarin (Coumadin)
2.	Cytochrome P-450 CYP2C19
3.	Cytochrome P-450 CYP3A
4.	Cytochrome P-450 CYP2C8
5.	Cytochrome P-450 Enzyme System (Cytochrome P450)
6.	Cytochrome P-450 CYP2B6 (CYP2B6)
7.	Cytochrome P-450 CYP2D6 (CYP2D6)
8.	Cytochrome P-450 CYP1A2 (CYP1A2)
9.	Enzymes
10.	Phenytoin (Dilantin)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Stents
4.	Chemoradiotherapy
5.	Secondary Prevention